A year on Wegovy\u00ae is the headline data point that built the entire GLP-1 obesity category. The STEP 1 trial (Wilding et al. 2021 NEJM) showed 14.9 percent mean weight loss at week 68 on 2.4 mg semaglutide. That number reshaped how clinicians and patients think about pharmacological weight management.<\/p>\n
Realistic 12 month results sit at 13 to 16 percent of starting body weight for adherent patients. For a 220 pound starting weight that means 29 to 35 pounds gone. Some responders push 18 to 20 percent; some stall earlier at 9 to 11 percent and need to consider switching to tirzepatide.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The mean 1 year weight loss on Wegovy is 13 to 16 percent of starting body weight for adherent patients on the standard 2.4 mg dose.<\/strong> That works out to 29 to 35 pounds at 220 pounds or 36 to 44 pounds at 280 pounds.<\/p>\n Quick Answer: Typical 1 year loss on Wegovy is 13 to 16 percent of starting body weight<\/p>\n STEP 1 (Wilding et al. 2021 NEJM), the foundational obesity trial, enrolled 1,961 adults on semaglutide 2.4 mg weekly for 68 weeks. Mean weight loss was 14.9 percent. At week 52 the number was about 13.5 percent.<\/p>\n The trial standard deviation was wide. About 32 percent of patients lost more than 20 percent of body weight; 14 percent of patients lost less than 5 percent. Response is bimodal in some ways, with strong responders and non-responders pulling the mean in opposite directions.<\/p>\n A 2024 real-world study from Truveta on 16,229 adults reported 41 percent adherence at 12 months. Adherent patients lost 9.5 to 11 percent on average, which is meaningfully below trial averages. The gap reflects dose timing, missed injections, and supply gaps.<\/p>\n The 1 year plateau usually starts between week 50 and 65 and represents the point where adaptive thermogenesis matches the appetite suppression effect.<\/strong> The scale stops moving for weeks at a time, with body composition still slowly improving.<\/p>\n STEP 1 weight loss curves show the steepest slope from weeks 4 to 28, gentler from week 28 to 52, and near-flat from week 52 to 68. The plateau is biological, not behavioral, and trying to push through with aggressive deficits usually backfires.<\/p>\n Sumithran and Proietto 2014 in Obesity journal documented appetite hormone changes after weight loss. Ghrelin, leptin, peptide YY, and other markers stay shifted toward weight regain for at least 12 months after major loss. GLP-1 medications blunt this defense but do not eliminate it.<\/p>\n Patients who keep losing past month 12 usually share two traits: consistent resistance training and high protein intake. Without those, the plateau holds and slight regain creeps in by month 14 or 15.<\/p>\n Metabolic improvements at year 1 are often more clinically meaningful than the weight loss itself.<\/strong> A1c reductions of 1.5 to 2.0 points in diabetic patients, systolic blood pressure drops of 5 to 8 mmHg, and triglyceride reductions of 25 to 35 percent are typical.<\/p>\n SELECT (Lincoff et al. 2023 NEJM) followed 17,604 non-diabetic adults with obesity and CVD on 2.4 mg semaglutide for a mean 39 months. The trial showed 20 percent reduction in major adverse cardiovascular events. Most of the surrogate metabolic shifts visible at month 6 were stable by month 12.<\/p>\n FLOW (Perkovic et al. 2024 NEJM) enrolled 3,533 patients with type 2 diabetes and CKD on 1 mg semaglutide. Over 3.4 years the trial showed 24 percent reduction in kidney failure and cardiovascular death. Kidney function stabilization was apparent in the first year.<\/p>\n STEP-HFpEF (Kosiborod et al. 2023 NEJM) showed semaglutide improved exercise capacity and symptoms in patients with heart failure and preserved ejection fraction, with most benefits visible by month 12.<\/p>\n Stopping Wegovy at 1 year typically leads to regaining about two-thirds of the lost weight within 12 months.<\/strong> This is the central finding from STEP 4 (Rubino et al. 2021 JAMA), the discontinuation extension of the STEP program.<\/p>\n STEP 4 randomized 803 responders after a 20 week lead-in on 2.4 mg semaglutide. Half continued the drug for another 48 weeks; half switched to placebo. The placebo group regained 6.9 percent of body weight. The continuation group lost another 7.9 percent.<\/p>\n The biological mechanism is the appetite hormone shift Sumithran documented. When semaglutide leaves the system, ghrelin rebounds, satiety signaling drops, and gastric emptying accelerates. Patients describe a sharp return of food noise within 2 to 3 weeks.<\/p>\n Practical implication: Wegovy at 1 year should be viewed like a blood pressure or cholesterol medication, ongoing rather than time-limited. Many providers try lower maintenance doses, 1 mg or 1.7 mg, after the loss phase to preserve results at lower cost and side effect burden.<\/p>\n Tirzepatide outperforms Wegovy at 1 year by 4 to 6 percentage points of weight loss in head-to-head comparisons.<\/strong> SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9 percent loss at week 72 on tirzepatide 15 mg versus 14.9 percent for semaglutide in STEP 1.<\/p>\n The two trials weren’t direct head-to-head but were similarly designed. The 6 percentage point gap is mechanistically explained by the dual GIP and GLP-1 agonism of tirzepatide versus GLP-1 alone with semaglutide.<\/p>\n For 220 pounds starting weight, that translates to 33 pounds on Wegovy versus 46 pounds on tirzepatide at 12 months. Side effect profiles are similar; the main differentiator is efficacy at the same time horizon.<\/p>\n SURMOUNT-5, the first direct head-to-head, reported in 2025 confirmed the tirzepatide advantage, with the dual agonist producing significantly more weight loss at 72 weeks. TrimRx’s personalized treatment plan includes both options.<\/p>\n Key Takeaway: Most patients hit a stable plateau between months 10 and 14<\/p>\n Real-world year 1 results on Wegovy are notably lower than STEP 1 trial averages, mostly because adherence drops sharply over the year.<\/strong> Trial conditions provide free medication, structured support, and monitoring that translate to better outcomes.<\/p>\n The 2024 Truveta cohort of 16,229 adults reported 41 percent adherence at 12 months. Among adherent patients, mean weight loss was 9.5 to 11 percent. Among all prescribed patients including dropouts, the figure was about 5.5 percent.<\/p>\n Cost and supply issues drive most discontinuations. Wegovy shortages in 2022 to 2024 forced switches and gaps that interrupted progress for many patients. Insurance coverage for chronic weight management remains uneven across plans.<\/p>\n Compounded semaglutide platforms like TrimRx can sidestep some supply and cost issues. Brand-name access has improved in 2025 and 2026, but the price gap remains significant for patients paying cash. The free assessment quiz is the standard entry point.<\/p>\n The standard protocol after a successful year 1 on Wegovy is continued therapy at the maintenance dose, with optional dose reduction if weight is stable and side effects are bothersome.<\/strong> SELECT extension data supports continued dosing for cardiovascular benefit.<\/p>\n A common shift at month 12 is dropping from 2.4 mg to 1.7 mg or even 1 mg, then watching for 3 months. If weight stays flat at the lower dose, that becomes the long-term maintenance dose. If regain starts within 8 to 12 weeks, the prior dose is reinstated.<\/p>\n Lifestyle work matters more in year 2 than year 1. The weight is off, the GLP-1 dose is doing less of the heavy lifting, and habits become the primary driver. Resistance training, sleep, protein, and step count are the levers that hold the result.<\/p>\n Lab monitoring at month 12 typically includes A1c, lipid panel, kidney function, liver enzymes, and vitamin B12. TrimRx’s personalized treatment plan covers annual labs and maintenance dose adjustments.<\/p>\n Wegovy has 2 to 4 year safety data from SELECT, FLOW, STEP-HFpEF, and the SUSTAIN diabetes program.<\/strong> The safety profile is strong with thyroid C-cell tumors (animal data only, no clear human signal), pancreatitis (under 1 percent), and gallbladder disease (about 3 to 4 percent) as the main flagged risks.<\/p>\n SELECT (Lincoff 2023 NEJM) followed 17,604 patients for a mean 39 months. Serious adverse events were similar between semaglutide and placebo groups. The cardiovascular benefit outweighed the side effect burden by a wide margin.<\/p>\n Long-term concerns remain. Muscle mass loss with prolonged calorie deficit, sarcopenia in older patients, and the unknowns of decade-long GLP-1 exposure are areas where data is still developing.<\/p>\n Annual monitoring is the standard practice. A1c, lipids, kidney function, liver enzymes, and vitamin B12 cover most of the surveillance. DEXA every 1 to 2 years to track body composition is increasingly common for patients on long-term therapy.<\/p>\n Bottom line: Long-term cardiovascular and kidney protection compounds through year 1 and beyond<\/p>\n Fifty pounds in 1 year is possible for patients starting above 270 pounds, where 50 pounds represents about 18 percent body weight loss. STEP 1 had about 14 percent of patients lose 20 percent or more, which would cover 50 pounds for many higher starting weights.<\/p>\n STEP 4 (Rubino 2021 JAMA) showed about two-thirds regain within 12 months of stopping. A patient who lost 35 pounds typically regains 22 to 25 pounds in the year after stopping without GLP-1 therapy.<\/p>\n Long-term safety data from SELECT, FLOW, and SUSTAIN through 2 to 4 years shows a strong safety profile. Annual monitoring is the standard practice. The thyroid tumor signal remains animal-only with no clear human evidence.<\/p>\n No, but weight loss usually plateaus between months 14 and 18. Therapy continues to maintain the lost weight and deliver cardiovascular and metabolic protection. New loss after the plateau is uncommon without dose changes or agent switching.<\/p>\n Many providers move from 2.4 mg down to 1 mg or 1.7 mg after the initial loss phase for long-term maintenance. The lower dose preserves most of the weight loss while reducing side effects and cost.<\/p>\n Most patients who want to keep the weight off stay on some GLP-1 long-term. Obesity is increasingly framed by ADA and AACE guidelines as a chronic condition with GLP-1 therapy as ongoing rather than time-limited.<\/p>\n For most patients, yes. A1c typically drops 1.5 to 2.0 percentage points in diabetic patients, blood pressure falls 5 to 8 mmHg, triglycerides drop 25 to 35 percent, and inflammatory markers like hs-CRP often improve. These changes match SELECT and SUSTAIN data.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" A year on Wegovy is the headline data point that built the entire GLP-1 obesity category. The STEP 1 trial (Wilding et al.<\/p>\n","protected":false},"author":11,"featured_media":93519,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Wegovy Results After 1 Year: Realistic Weight Loss Expectations","_yoast_wpseo_metadesc":"A year on Wegovy is the headline data point that built the entire GLP-1 obesity category. The STEP 1 trial (Wilding et al.","_yoast_wpseo_focuskw":"wegovy results after","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[13],"tags":[42,55,56],"class_list":["post-90983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-wegovy","tag-results","tag-wegovy","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90983"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90983\/revisions"}],"predecessor-version":[{"id":92043,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90983\/revisions\/92043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93519"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Year 1 Plateau Look Like?<\/h2>\n
How Do Year 1 Metabolic Results Compare to Weight Results?<\/h2>\n
What Happens If You Stop Wegovy at 1 Year?<\/h2>\n
How Does Wegovy Compare to Tirzepatide at 1 Year?<\/h2>\n
What Real-world Year 1 Results Look Like<\/h2>\n
What Does the Year 1 Protocol Look Like for Year 2?<\/h2>\n
Is Wegovy Safe for Long-term Use?<\/h2>\n
FAQ<\/h2>\n
Can You Lose 50 Pounds in 1 Year on Wegovy?<\/h3>\n
How Much Weight Do You Regain After Stopping Wegovy?<\/h3>\n
Is Wegovy Safe to Take for Years?<\/h3>\n
Does Wegovy Stop Working After a Year?<\/h3>\n
What’s the Best Dose for Long-term Wegovy Maintenance?<\/h3>\n
Do You Need to Be on Wegovy Forever?<\/h3>\n
Will My Labs Improve by 1 Year on Wegovy?<\/h3>\n